Skip to content

Adarx Pharmaceuticals

US · ADRX #2823 by market cap Listed 2026
12.79 -1.37 -9.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Financial Health how this is computed

Weak
  • Altman Z-Score is 1.12, below the 1.8 "distress zone" threshold.
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 2 years

Margins

Operating margin
-2,562.05%
Net margin
-2,119.11%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2024 2025
Revenue 03.45M
Gross profit ----
Selling & admin expenses 14.88M20.30M
Research & development 43.36M71.51M
Operating profit -58.23M-88.37M
Pretax profit -46.36M-73.09M
Tax ----
Net profit -46.36M-73.09M
Basic EPS -1-1
Diluted EPS -0.62-0.97

Balance sheet

Line item 2024 2025
Total current assets 225.67M493.38M
Cash & ST investments 219.48M480.00M
Inventory ----
Total assets 233.45M507.66M
Total current liabilities 8.94M30.49M
Short-term debt 794.00K1.71M
Long-term debt ----
Total liabilities 370,599,000.00709,910,000.00
Total equity -137.15M-202.26M
Retained earnings -147.61M-220.70M

Cash flow

Line item 2024 2025
Operating cash flow -48.56M262.29M
Depreciation & amortization 1.50M2.33M
Free cash flow -49.02M259.35M
Dividends paid ----
Stock buybacks / issuance ----
Ending cash balance 14.03M66.52M

Returns & efficiency

Line item 2024 2025
ROE % ----
ROA % -19.86-19.72
ROIC % ----
5-year avg ROE % ----
EBIT margin % ---2,562.05
FCF / sales % --7,519.66
Current ratio 25.2516.18
Quick ratio 24.5615.75
Debt / assets 1.851.52
LT debt / equity ----
Interest coverage ----
Revenue CAGR (3Y) % ----
Net income CAGR (3Y) % ----
FCF CAGR (3Y) % ----

Revenue breakdown most recent period

Business

Developing proprietary RNA targeting delivery platforms as well as technologies for silencing or100.00%

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adarx Pharmaceuticals discussion 0 comments

Add a comment